Literature DB >> 10599485

Current treatments of the anxiety disorders in adults.

J C Ballenger1.   

Abstract

The progress in developing effective treatments for the five principal anxiety disorders (ADs) in adults--panic disorder (PD), social phobia (SP), obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD)--has been rapid in the past 15 years. There are now well-controlled clinical trials documenting effective pharmacological and psychological treatments for all of these disorders, although generally the evidence is better developed for some disorders than for others. Both the pharmacological treatments and the effective psychological treatments for each disorder will be briefly reviewed. The available data for combination treatment will be reviewed and comparisons of the two types of treatment will be made. This review will contain at least brief reviews of what the treatments involve and attempt to describe how well they work. Many studies unfortunately report only the percentage of patients who "improve" without quantifying the clinical significance of those responses. Data underlining clinical response in terms of the percentage of patients who have an "excellent," "marked," or "moderate" response, and the percentage of patients with a "clinically significant" response will be reported whenever available. Other clinically relevant issues such as length of treatment-relapse rates upon discontinuation and side effects will be presented. As such, this article should provide a brief but comprehensive review of the treatment of these disorders in adults.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10599485     DOI: 10.1016/s0006-3223(99)00220-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  23 in total

Review 1.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

2.  Escitalopram in obsessive-compulsive disorder: a case series.

Authors:  Amit Zutshi; Suresh Bada Math; Y C Janardhan Reddy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Authors:  Michael Rufer; Iver Hand; Heike Alsleben; Anne Braatz; Jürgen Ortmann; Birgit Katenkamp; Susanne Fricke; Helmut Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

4.  The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats.

Authors:  Xia Li; Katarzyna Kaczanowska; M G Finn; Athina Markou; Victoria B Risbrough
Journal:  Neuropharmacology       Date:  2015-05-19       Impact factor: 5.250

5.  Neural Circuitry of Interoception: New Insights into Anxiety and Obsessive-Compulsive Disorders.

Authors:  Emily R Stern
Journal:  Curr Treat Options Psychiatry       Date:  2014-06-21

Review 6.  Modeling anxiety using adult zebrafish: a conceptual review.

Authors:  Adam Stewart; Siddharth Gaikwad; Evan Kyzar; Jeremy Green; Andrew Roth; Allan V Kalueff
Journal:  Neuropharmacology       Date:  2011-08-09       Impact factor: 5.250

Review 7.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Anxiety and Depression: Optimizing Treatments.

Authors:  James C. Ballenger
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06

9.  A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care.

Authors:  James C. Ballenger; Jonathan R. T. Davidson; Yves Lecrubier; David J. Nutt
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

Review 10.  The hormonal control of ejaculation.

Authors:  Giovanni Corona; Emmanuele A Jannini; Linda Vignozzi; Giulia Rastrelli; Mario Maggi
Journal:  Nat Rev Urol       Date:  2012-08-07       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.